Danny Burg (PhD, ERT) is a dependable, results-driven drug discovery and development expert. He has a background in toxicology and oncology drug development. His 20 years of experience include research positions at the Netherlands Cancer Institute and Leiden University, and his experience covers bioanalysis, drug metabolism and biomarker expertise (GLP), and nonclinical toxicology support of early and late phase small and large molecules.

Danny has experience with all phases of drug development, including designing and executing nonclinical drug development programs, Environmental Risk Assessment reports (ERA’s) and scientific training of commercial organizations. He has been instrumental in the submission of multiple MAA/NDAs for oncology products.   

Danny has a special interest in (immuno) oncology projects, mechanistic assessments, evaluating the value of novel projects (e.g. due diligence preparation and assessment).